Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in promoting weight loss and improving metabolic health.

Researchers at the Pennington Biomedical Research Center have found new clues about how the drug tirzepatide, also known by ...

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Investigators sourced data for this study from the TriNetX Analytics Research Network database. Patients (N=1,999,881) diagnosed with AF between 2022 and 2024 and who used tirzepatide for diabetes ...